hVIVO acquires CRS units for €10 million
LONDON: hVIVO plc, a leading human challenge clinical trials organization, has acquired two clinical research units from German CRO CRS Clinical Research Services Management GmbH...
Data shows SARS-CoV-2 human challenge studies safe in healthy young adults
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge...
Open Orphan’s hVIVO to manufacture a SARS-CoV-2 challenge virus
LONDON: hVIVO, a subsidiary of Open Orphan plc (LON: ORPH), has signed a contract with Imperial College London, as part of a Wellcome Trust funded...